Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)

Docetaxel plus cisplatin and docetaxel plus irinotecan are active and well-tolerated chemotherapy regimens for advanced non-small-cell lung cancer (NSCLC). A randomised phase II study compared their efficacy and toxicity in 108 patients with stage IIIb/IV NSCLC, who were randomised to receive doceta...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yamamoto, N, Fukuoka, M, Negoro, S-I, Nakagawa, K, Saito, H, Matsui, K, Kawahara, M, Senba, H, Takada, Y, Kudoh, S, Nakano, T, Katakami, N, Sugiura, T, Hoso, T, Ariyoshi, Y
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2004
Aiheet:
Clinical
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2395326/
https://ncbi.nlm.nih.gov/pubmed/14710212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601462
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia